Xenetic Biosciences (XBIO) Announces Favorable Data from Third Cohort of ErepoXen Phase 3 in Anemia
Tweet Send to a Friend
Xenetic Biosciences, Inc. (OTC: XBIO) announced positive topline data from the third cohort of its Phase 2 dose-escalation study with ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
